Skip to content
Sign inOpen the app
Pharmaceutical Executive

Pharmaceutical Executive Daily: Eli Lilly Reports Positive Results from Two Phase III Trials

July 23 · 3 min · 3.1 MB
0:00-3:16

Streams straight from the publisher. podnod never proxies or re-hosts episode audio.

Open in podnod

In today's Pharmaceutical Executive Daily, Eli Lilly's Retatrutide delivers up to 22.6% weight loss in two new Phase III trials, a clinical trial expert discusses why the U.S. is losing trial volume to Australia and China, and a pharmacy benefits executive weighs in on why short-term cost thinking is complicating GLP-1 coverage decisions.